Xpert MTB/RIF Ultra on contaminated liquid cultures for tuberculosis and rifampicin-resistance detection

• Verfasst von: Ghebrekristos, Yonas [VerfasserIn]
• Verfasst von: Beylis, Natalie [VerfasserIn]
• Verfasst von: Centner, Chad M. [VerfasserIn]
• Verfasst von: Venter, Rouxjeane [VerfasserIn]
• Verfasst von: Derendinger, Brigitta [VerfasserIn]
• Verfasst von: Tshivhula, Happy [VerfasserIn]
• Verfasst von: Naidoo, Selisha [VerfasserIn]
• Verfasst von: Alberts, Rencia [VerfasserIn]
• Verfasst von: Prins, Bronwyn [VerfasserIn]
• Verfasst von: Tokota, Anitta [VerfasserIn]
• Verfasst von: Dolby, Tania [VerfasserIn]
• Verfasst von: Marx, Florian [VerfasserIn]
• Verfasst von: Omar, Shaheed V. [VerfasserIn]
• Verfasst von: Warren, Robin [VerfasserIn]
• Verfasst von: Theron, Grant [VerfasserIn]
• Titel: Xpert MTB/RIF Ultra on contaminated liquid cultures for tuberculosis and rifampicin-resistance detection
• Titelzusatz: a diagnostic accuracy evaluation
• Verf.angabe: Yonas T Ghebrekristos, Natalie Beylis, Chad M Centner, Rouxjeane Venter, Brigitta Derendinger, Happy Tshivhula, Selisha Naidoo, Rencia Alberts, Bronwyn Prins, Anitta Tokota, Tania Dolby, Florian Marx, Shaheed V Omar, Robin Warren, Grant Theron
• E-Jahr: 2023
• Jahr: October 2023
• Umfang: 8 S.
• Fussnoten: Online veröffentlicht: 19. September 2023 ; Gesehen am 19.08.2024
• Titel Quelle: Enthalten in: The lancet. Microbe
• Ort Quelle: Amsterdam : Elsevier, 2020
• Jahr Quelle: 2023
• Band/Heft Quelle: 4(2023,10), Oktober, Seite e822-e829
• ISSN Quelle: 2666-5247
• DOI: doi:10.1016/S2666-5247(23)00169-6
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1899111174

Abstract

Background - Xpert MTB/RIF Ultra (Ultra) is a widely used rapid front-line tuberculosis and rifampicin-susceptibility testing. Mycobacterium Growth Indicator Tube (MGIT) 960 liquid culture is used as an adjunct but is vulnerable to contamination. We aimed to assess whether Ultra can be used on to-be-discarded contaminated cultures. - Methods - We stored contaminated MGIT960 tubes (growth-positive, acid-fast bacilli [AFB]-negative) originally inoculated at a high-volume laboratory in Cape Town, South Africa, to diagnose patients with presumptive pulmonary tuberculosis. Patients who had no positive tuberculosis results (smear, Ultra, or culture) at contamination detection and had another, later specimen submitted within 3 months of the contaminated specimen were selected. We evaluated the sensitivity and specificity of Ultra on contaminated growth from the first culture for tuberculosis (next-available non-contaminated culture result reference standard) and rifampicin resistance (vs MTBDRplus on a later isolate). We calculated potential time-to-diagnosis improvements and also evaluated the immunochromatographic MPT64 TBc assay. - Findings - Between June 1 and Aug 31, 2019, 36 684 specimens from 26 929 patients were processed for diagnostic culture. 2402 (7%) cultures from 2186 patients were contaminated. 1068 (49%) of 2186 patients had no other specimen submitted. After 319 exclusions, there were 799 people with at least one repeat specimen submitted; of these, we included in our study 246 patients (31%) with a culture-positive repeat specimen and 429 patients (54%) with a culture-negative repeat specimen. 124 patients (16%) with a culture-contaminated repeat specimen were excluded. When Ultra was done on the initial contaminated growth, sensitivity was 89% (95% CI 84-94) for tuberculosis and 95% (75-100) for rifampicin-resistance detection, and specificity was 95% (90-98) for tuberculosis and 98% (93-100) for rifampicin-resistance detection. If our approach were used the day after contamination detection, the time to tuberculosis detection would improve by a median of 23 days (IQR 13-45) and provide a result in many patients who had none. MPT64 TBc had a sensitivity of 5% (95% CI 0-25). - Interpretation - Ultra on AFB-negative growth from contaminated MGIT960 tubes had high sensitivity and specificity, approximating WHO criteria for sputum test target product performance and exceeding drug susceptibility testing. Our approach could mitigate negative effects of culture contamination, especially when repeat specimens are not submitted. - Funding - The European & Developing Countries Clinical Trials Partnership, National Institutes of Health.